- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Revolution Medicines, Inc.
- Phone Number: (650) 779-2300
- Email: rmc-6236_ct-inquiry@revmed.com
Study Locations
-
-
California
-
Orange, California, United States, 92868
- Recruiting
- UC Irvine/Chao Family Comprehensive Cancer Center
-
Santa Monica, California, United States, 90404
- Recruiting
- UCLA
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10021
- Recruiting
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, United States, 10032
- Recruiting
- Columbia University
-
New York, New York, United States, 10016
- Recruiting
- Perlmutter Cancer Center at NYU Langone Health
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- Christ Hospital Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Research Institute
-
-
Texas
-
Austin, Texas, United States, 78712
- Recruiting
- University of Texas at Austin
-
Dallas, Texas, United States, 75230
- Recruiting
- Mary Crowley Cancer Research
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Md Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- Recruiting
- Next Oncology
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Next Oncology Virginia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing.
- Received prior standard therapy appropriate for tumor type and stage
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
Exclusion Criteria:
- Primary central nervous system (CNS) tumors
- Active, untreated brain metastases
- Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
- History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
Other inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: RMC-6236
Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations. Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, PDAC, CRC, Melanoma, gynecological cancer or other solid tumors not previously specified). RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61) |
Oral Tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs
Time Frame: up to 2.5 years
|
up to 2.5 years
|
Number of Participants with Dose-Limiting Toxicity (DLT)
Time Frame: 21 days
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Blood Concentration (Cmax) of RMC-6236
Time Frame: up to 15 weeks
|
up to 15 weeks
|
|
Time to Reach Maximum Blood Concentration (Tmax) of RMC-6236
Time Frame: up to 15 weeks
|
up to 15 weeks
|
|
Area Under Blood Concentration Time Curve (AUC) of RMC-6236
Time Frame: up to 15 weeks
|
up to 15 weeks
|
|
Elimination Half-Life of RMC-6236 (t1/2)
Time Frame: up to 15 weeks
|
up to 15 weeks
|
|
Ratio of accumulation of RMC-6236 from a single dose to steady state with repeated dosing
Time Frame: up to 15 weeks
|
up to 15 weeks
|
|
Overall Response Rate (ORR)
Time Frame: up to 2.5 years
|
Overall response rate per RECIST v1.1
|
up to 2.5 years
|
Duration of Response (DOR)
Time Frame: up to 2.5 years
|
Duration of response per RECIST v1.1
|
up to 2.5 years
|
Disease Control Rate (DCR)
Time Frame: up to 2.5 years
|
Disease control rate per RECIST v1.1
|
up to 2.5 years
|
Time to Response (TTR)
Time Frame: up to 2.5 years
|
Time to response per RECIST v1.1
|
up to 2.5 years
|
Progression-Free Survival (PFS)
Time Frame: up to 2.5 years
|
Progression-free survival per RECIST v1.1
|
up to 2.5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Revolution Medicines, Inc., Revolution Medicines, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Lung Cancer
- NSCLC
- Pancreatic Cancer
- Melanoma
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Metastatic Cancer
- Colon Cancer
- Non-small Cell Lung Cancer
- Thoracic Neoplasms
- Colorectal Neoplasms
- KRAS
- CRC
- Pancreatic Neoplasms
- PDAC
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- RAS
- Colonic Neoplasms
- Lung Neoplasms
- Carcinoma, Pancreatic Ductal
- Neoplastic Processes
- Gynecological Cancers
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Adenocarcinoma
Other Study ID Numbers
- RMC-6236-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
Clinical Trials on RMC-6236
-
Revolution Medicines, Inc.RecruitingNon-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, CancerUnited States
-
Revolution Medicines, Inc.Active, not recruitingSolid TumorsUnited States
-
Revolution Medicines, Inc.SanofiActive, not recruitingSolid TumorsUnited States
-
Nicholas ButowskiNational Cancer Institute (NCI); Revolution Medicines, Inc.RecruitingGlioblastoma | Recurrent GlioblastomaUnited States
-
Chestnut Health SystemsRecruitingOpioid-use DisorderUnited States
-
The Netherlands Cancer InstituteLustgarten FoundationRecruitingColorectal Cancer | Pancreatic Cancer | Non-small Cell Lung Cancer | KRAS Mutation-Related TumorsNetherlands
-
Revolution Medicines, Inc.Sanofi; AmgenActive, not recruitingNon-Small Cell Lung CancerUnited States, Korea, Republic of, Canada, Taiwan, Spain, United Kingdom, Italy, Australia, France, Germany
-
Revolution Medicines, Inc.RecruitingAdvanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)United States
-
University Hospital TuebingenJohannes Gutenberg University Mainz; Heinen und Löwenstein GmbH & Co. KGCompletedInfant Respiratory Distress Syndrome | Ventilator Lung; NewbornGermany
-
Revolution Medicines, Inc.RecruitingAdvanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC) | Colorectal Cancer (CRC)United States, Italy, Spain, Malaysia, Korea, Republic of, France, Australia, Thailand, Taiwan, Poland, Singapore, Czechia, Serbia